Join to View Full Profile
27 Dale DrChatham, NJ 07928
Phone+1 973-210-7327
Dr. Dangond is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1990 - 1994
Columbia Saint Luke's Medical CenterResidency, Internal Medicine, 1988 - 1990
Pontifical Xavierian UniversityClass of 1987
Certifications & Licensure
NJ State Medical License 2007 - 2027
MA State Medical License 1992 - 2025
American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 3 citationsTwenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives.Mark S Freedman, Patricia K Coyle, Kerstin Hellwig, Barry Singer, Daniel Wynn
Neurology and Therapy. 2024-04-01 - Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.Gavin Giovannoni, Giancarlo Comi, Kottil Rammohan, Peter Rieckmann, Fernando Dangond
Neurodegenerative Disease Management. 2022-12-01 - Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.Nicola De Stefano, Maria Pia Sormani, Gavin Giovannoni, Kottil Rammohan, Thomas P Leist
Neurodegenerative Disease Management. 2022-12-01
Press Mentions
Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of SafetyJune 24th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
